Fondazione Ricerca Traslazionale — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

5 Recruiting

0 Completed trials

3 Countries active

15 Unique IMPs

N/A Results reported

Phase II

Phase II: 8

Top indications

Non-small cell lung cancer 4 Non-small cell lung cancer stage III 1

Top IMPs

PEMETREXED 3 MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-214, D-ALA-LYS-CHA-VAL-ALA-ALA-TRP-THR-LEU-LYS-ALA-ALA-D-ALA, MPS-200 2 AMIVANTAMAB 1 ATEZOLIZUMAB 1 BEVACIZUMAB 1 CABOZANTINIB 1 CARBOPLATIN 1 CEMIPLIMAB 1 CISPLATIN 1 DACOMITINIB 1 DURVALUMAB 1 OSIMERTINIB 1

All trials

8 total

Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending

2024-518386-95-02 Phase II 1 country CABOZANTINIB
Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiot… Pending

2024-520081-65-00 Phase II 1 country DURVALUMAB
Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending

2025-520676-26-00 Phase II 1 country AMIVANTAMAB; PEMETREXED
A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-li… Recruiting

2024-518224-74-01 Phase II 3 countries MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-214, D-ALA-LY…
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s… Recruiting

2024-518223-29-00 Phase II 2 countries DACOMITINIB; OSIMERTINIB
Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance therapy in ctDNA positive NSCLC. Recruiting

2024-519262-42-00 Phase II 1 country CEMIPLIMAB; MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-2…
Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) Recruiting

2024-519205-35-01 Phase II 1 country CARBOPLATIN; CISPLATIN; PACLITAXEL; PEMETREXED; TISLELIZUMAB
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm… Recruiting

2024-517200-10-00 Phase II 1 country ATEZOLIZUMAB; BEVACIZUMAB

Showing 1–8 of 8 trials

← All sponsors A–Z